| Assessment Status | Rapid Review complete |
| HTA ID | 21050 |
| Drug | Baricitinib |
| Brand | Olumiant® |
| Indication | Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 09/11/2021 |
| Rapid review completed | 16/12/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.